Skip to main content

Surgery Partners Inc

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

SGRY$26.73+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, dollars in millions)

Six Months Ended June 30,
20242023
Cash flows from operating activities:
Net income$52.7$58.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization68.558.1
Non-cash lease expense18.717.9
Non-cash interest expense, net3.113.1
Equity-based compensation expense20.08.8
Net loss on disposals, consolidations and deconsolidations6.81.7
Loss on debt extinguishment5.1—
Deferred income taxes7.6(11.5)
Equity in earnings of unconsolidated affiliates, net of distributions received0.2(0.8)
Changes in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable(12.1)(5.1)
Medicare accelerated payments and deferred governmental grants—(1.2)
Other operating assets and liabilities(47.1)(13.3)
Net cash provided by operating activities123.5126.6
Cash flows from investing activities:
Purchases of property and equipment(47.9)(50.1)
Payments for acquisitions, net of cash acquired(264.6)(43.5)
Proceeds from disposals of facilities and other assets1.526.1
Purchases of equity investments(1.7)(48.4)
Proceeds from sales of equity investments4.0—
Other investing activities(18.5)(26.0)
Net cash used in investing activities(327.2)(141.9)
Cash flows from financing activities:
Principal payments on long-term debt(973.8)(31.5)
Borrowings of long-term debt1,295.426.5
Payments of debt issuance costs(14.9)(1.4)
Distributions to non-controlling interest holders(80.7)(76.9)
Proceeds related to ownership transactions with non-controlling interest holders1.00.6
Other financing activities(5.7)(7.5)
Net cash provided by (used in) financing activities221.3(90.2)
Net increase (decrease) in cash and cash equivalents17.6(105.5)
Cash and cash equivalents at beginning of period195.9282.9
Cash and cash equivalents at end of period$213.5$177.4
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.